- West Island Brands Inc. (CSE:WIB) subsidiary, RoyalMax Biotechnology Canada Inc. has achieved one million dollars in revenue for the month of March 2022
- This increase in revenue comes on the heels of the company’s entry into the province of Ontario
- The month-to-month increase over the previous month’s sales represents an approximate 200 percent increase in revenue
- Beginning in May, two OUEST brand premium SKU’s will be available in the province with the addition of Grand Pa’s stash
- By 13:02 ET, West Island Brands Inc (WIB) was trading at $0.40, having gained $0.09 or 29.03 per cent
West Island Brands (WIB) subsidiary, RoyalMax Biotechnology Canada has achieved one million dollars in revenue for the month of March.
This increase in revenue comes on the heels of the company’s entry into the province of Ontario.
The month-to-month increase over the previous month’s sales represents an approximate 200 percent increase in revenue.
This increase was largely the result of a new SKU (stock keeping unit), Platinum Cake, in Ontario.
Beginning in May, two OUEST brand premium SKUs will be available in the province with the addition of Grand Pa’s stash.
“The province of Ontario is the largest market for cannabis in Canada and has an appetite for the high THC, terpene-rich premium product in which West Island specializes,” said Boris Ziger, CEO of West Island.
“As we build on our success in Ontario we will continue our entry into other markets, beginning with sales in the province of Quebec, in the near future,” he added.
West Island is a multi-faceted company in the Quebec cannabis space.
Its subsidiary, RoyalMax Biotechnology Canada Inc., is a Dorval, Quebec-based Health Canada License Holder with standard cultivation license, standard processing, medical sales and sales licenses.
By 13:02 ET, West Island Brands Inc (WIB) was trading at $0.40, having gained $0.09 or 29.03 per cent.
